The Zhitong Finance App learned that on Friday, Zaiding Pharmaceutical (ZLAB.US) rose nearly 10% at the beginning of the session. As of press release, it had risen more than 2% to $22.62. According to the news, on October 23, Zaiding Pharmaceutical announced global phase Ib clinical research data for its antibody-conjugated drug (ADC) Zocilurtatug Pelitecan (“Zoci”, original code name ZL-1310) for first-line broad-stage small cell lung cancer. The relevant results will be presented at the 2026 European Society of Medical Oncology (ESMO) conference on October 26.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.